37,521 Shares in PROCEPT BioRobotics Co. (NASDAQ:PRCT) Bought by EAM Global Investors LLC

EAM Global Investors LLC bought a new position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 37,521 shares of the company's stock, valued at approximately $3,021,000. EAM Global Investors LLC owned approximately 0.07% of PROCEPT BioRobotics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of PRCT. Raleigh Capital Management Inc. bought a new stake in shares of PROCEPT BioRobotics in the 4th quarter worth about $32,000. Signaturefd LLC grew its position in shares of PROCEPT BioRobotics by 26.7% in the 4th quarter. Signaturefd LLC now owns 689 shares of the company's stock worth $55,000 after acquiring an additional 145 shares in the last quarter. IFP Advisors Inc acquired a new stake in shares of PROCEPT BioRobotics during the 4th quarter valued at approximately $58,000. Arcadia Investment Management Corp MI bought a new position in PROCEPT BioRobotics during the fourth quarter worth $64,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in PROCEPT BioRobotics during the third quarter valued at $64,000. 89.46% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of the business's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the completion of the sale, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at approximately $9,875,374.20. The trade was a 3.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Kevin Waters sold 733 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the sale, the chief financial officer now owns 107,991 shares of the company's stock, valued at $6,161,966.46. This trade represents a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,455 shares of company stock worth $368,322. Company insiders own 17.40% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on PRCT shares. Truist Financial decreased their price target on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a report on Friday, April 11th. Morgan Stanley cut their price objective on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, PROCEPT BioRobotics currently has an average rating of "Moderate Buy" and an average target price of $91.43.

PROCEPT BioRobotics Stock Up 0.3 %

NASDAQ:PRCT traded up $0.16 during trading hours on Monday, reaching $53.19. The company's stock had a trading volume of 538,472 shares, compared to its average volume of 781,316. PROCEPT BioRobotics Co. has a one year low of $47.04 and a one year high of $103.81. The business's 50-day moving average is $59.16 and its 200-day moving average is $74.66. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. The company has a market cap of $2.92 billion, a price-to-earnings ratio of -27.28 and a beta of 1.09.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The business had revenue of $68.24 million during the quarter, compared to the consensus estimate of $66.79 million. Equities research analysts predict that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).